Quinolone Ophthalmic Suspension Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic formulations of fluoroquinolone antibiotics face challenges such as instability, flocculation, and reduced efficacy due to interactions with ocular tissues, necessitating the development of stable and effective compositions that maintain antimicrobial and anti-inflammatory properties.
Innovation Solution
The development of ophthalmologically suitable compositions comprising a fluoroquinolone antibiotic, an anti-inflammatory steroid, and a combination of ionic and non-ionic suspension agents, along with a chelating agent, to create physically and chemically stable suspensions that enhance the stability and distribution of active ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fluoroquinolone antibiotic compositions are used to treat ophthalmic infections, then broad-spectrum antimicrobial activity is achieved, but instability and flocculation occur due to interactions with ocular tissues
Solution Approach 1:
The patent introduces a complexing agent (such as EDTA or citrate) as an intermediary substance that binds to metal ions in the formulation. This complexing agent prevents direct interaction between the fluoroquinolone antibiotic and metal ions that would otherwise cause instability and flocculation, thereby maintaining both broad-spectrum antimicrobial activity and formulation stability simultaneously
Solution Approach 2:
The patent creates a composite ophthalmic formulation that combines the fluoroquinolone antibiotic with a complexing agent and other excipients in a synergistic mixture. This composite formulation leverages the antimicrobial properties of the fluoroquinolone while the complexing agent and excipients work together to prevent flocculation and enhance overall stability, resolving the contradiction between efficacy and stability
2Stability of the object's composition
If suspension agents are added to improve physical stability, then flocculation is reduced, but formulation complexity increases
Solution Approach 1:
The patent selects complexing agents that serve multiple functions: they complex with metal ions to prevent flocculation, maintain formulation stability, and in some cases contribute to the overall antimicrobial efficacy or enhance the solubility of the antibiotic. This multi-functionality reduces the need for additional separate stability-enhancing additives, thereby limiting the increase in formulation complexity while achieving improved physical stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed compositions achieve improved stability and broad-spectrum antibiotic activity, reducing flocculation and coagulation, while maintaining therapeutic effectiveness and safety for ocular use.
Implementation Method 1
a pharmaceutically acceptable chelating agent that results in a significantly similar or improved stability of the active ingredients
Implementation Method 2
an ophthalmologically suitable composition in the form of a solution or suspension comprising: (a) a suspension component consisting of both (1) an effective amount of at least one non-ionic suspension agent and (2) an effective amount of at least one ionic suspension agent
Data Source
AI summary
Provided are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a quinolone antibiotic, e.g., a fourth-generation fluoroquinolone, and an effective amount of an anti-inflammatory agent. In aspects, the anti-inflammatory agent is an anti-inflammatory steroid, NSAID, or a combination thereof. In aspects, compositions are stable suspensions, which maintain physical and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical conditions). In aspects, compositions are suspensions including a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, compositions also or alternatively comprise a non-ionic surfactant, non-ionic suspension agent, or both, or an agent providing both functions. In aspects, compositions further comprise a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in treating or preventing of bacterial eye infections.